Life-Saving Medicines: Affordability, Right to Health and Business Ethics

LIFE-SAVING MEDICINES: AFFORDABILITY, RIGHT TO HEALTH AND BUSINESS ETHICS

• Recently a Supreme Court Bench of Justices Vikram Nath and Sandeep Mehta questioned steep differences between the maximum retail price (MRP) of medicines and the price to retailers (PTR). 
• Hearing petitions on affordable medicines, the Court challenged whether commercial considerations should outweigh patients’ lives. It reserved its order; these oral observations are not a final judgment.

What Is the Issue?

• Life-saving drugs, including cancer medicines, can place a severe burden on families when distribution mark-ups and hospital charges push prices beyond affordability. 
• The policy question is not whether pharmaceutical companies may earn profits, but how to prevent excessive margins without undermining quality, innovation or uninterrupted supply. Scheduled formulations have notified ceiling prices; non-scheduled formulations are monitored too, but generally do not face the same upfront ceiling-price regime.

Constitutional and Legal Background

• Article 21 protects life and personal liberty, and Article 47 directs the State to improve public health. In Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996), the Supreme Court held that failure to provide timely medical treatment in government hospitals can violate Article 21. 
• The Drugs (Prices Control) Order (DPCO), 2013, issued under the Essential Commodities Act, 1955, is implemented by the National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals. 
• The Health Ministry prepares the National List of Essential Medicines (NLEM); relevant medicines are incorporated into Schedule I of DPCO for direct price control.

Data and Recent Government Action

• The National Health Accounts 2022–23 put out-of-pocket spending at 43.4% of India’s total health expenditure. On 17 October 2026, NPPA notified trade-margin rationalisation for 137 specified non-scheduled anti-cancer drugs, capping the trade margin at 30% of MRP. 
• Revised prices are due to take effect on 9 November 2026; the government anticipates possible reductions of up to 70% for affected products and estimates annual patient savings of ₹2,500 crore. These are projected benefits, not realised savings.

Causes, Significance and Challenges

• Opaque distributor discounts, weak price transparency, differences between hospital procurement and billing prices, limited patient bargaining power and high treatment costs can create financial distress. For a cancer patient, postponing treatment because of price may carry irreversible consequences. 
• Yet blanket price cuts, if poorly designed, may discourage supply of low-volume medicines or investment in research. The regulatory task is therefore to distinguish legitimate production and service costs from unjustified mark-ups, and to enforce rules without causing shortages.

Multidimensional and Ethical Analysis

• From an economic perspective, medicines are not ordinary discretionary goods: an ill patient often cannot delay consumption or negotiate. Socially, unaffordable treatment deepens inequality; constitutionally, it raises questions about effective access to healthcare.

Examples and Government Initiatives

• The Supreme Court hearing cited large gaps between acquisition prices and hospital bills for certain products, illustrating the need for auditable pricing. Under DPCO, paragraph 19 allows exceptional public-interest price intervention; paragraph 20 monitors increases in non-scheduled medicine prices, generally limiting manufacturer MRP increases to 10% over the preceding twelve months. 
• The Pradhan Mantri Bhartiya Janaushadhi Pariyojana supplies lower-cost generic medicines; Ayushman Bharat PM-JAY provides eligible families with up to ₹5 lakh annual cover for specified hospitalisation.

Way Forward and Conclusion

• India needs itemised hospital bills, publicly searchable MRPs and procurement prices, timely NPPA enforcement, stronger generic prescribing, effective complaints mechanisms and periodic updates to essential-medicine coverage. Price policy should monitor availability and reward meaningful pharmaceutical innovation while preventing exploitative trade margins. 
• Healthcare affordability is ultimately a matter of public trust: a credible system must respect commercial sustainability without allowing the inability to pay to determine who receives timely treatment.

MCQs

Q1. With reference to drug-price regulation in India, consider the following statements:

1. The National List of Essential Medicines is prepared by the Ministry of Health and Family Welfare.
2. Non-scheduled formulations are entirely exempt from price monitoring under DPCO, 2013.
3. Paragraph 19 of DPCO, 2013, permits price intervention in extraordinary circumstances in the public interest.

Which of the statements given above are correct?

(A) 1 and 2 only

(B) 1 and 3 only

(C) 2 and 3 only

(D) 1, 2 and 3

Answer—(B)

Explanation: Statement 2 is incorrect. Paragraph 20 provides monitoring of non-scheduled prices, including limits on annual MRP increases.